SequelSEC

NEOGENOMICS INC NEO

Services-Testing Laboratories · CIK 0001077183 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$209.25M
Fiscal year ended 2026-09-30
Operating income
-$7.94M
Fiscal year ended 2026-09-30
Free cash flow
-$20.66M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$680.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

Valuation over time

671.1× earnings today, against a median of 299.5× across 3 years on record. Above its own history.

Float measuredPublic floatFloat / net income
2020-06-30$2.80B671.1×
2019-06-30$1.90B237.3×
2018-06-30$790.60M299.5×

Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.

NEOGENOMICS INC (NEO) reported revenue of $209.25M and net income of -$7.55M for the fiscal year ended 2026-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from NEOGENOMICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Testing Laboratories.

Income

NEOGENOMICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Revenue$209.25M$201.66M$186.67M$190.17M$187.80M$181.33M$168.04M$172.00M$167.82M$164.50M
Cost of revenue$112.67M$109.78M$105.81M$106.83M$107.35M$104.07M$94.79M$94.74M$92.94M$92.01M
Gross profit$96.59M$91.88M$80.86M$83.34M$80.45M$77.26M$73.25M$77.26M$74.88M$72.49M
Operating income-$7.94M-$9.77M-$18.24M-$13.41M-$27.01M-$47.63M-$27.82M-$18.40M-$21.20M-$21.94M
Net income-$7.55M$2.24M-$17.11M-$9.88M-$27.13M-$45.09M-$25.92M-$15.32M-$17.70M-$18.64M
Research & development$9.86M$10.76M$9.53M$9.18M$8.69M$9.02M$10.18M$7.97M$7.68M$7.89M
Weighted-average diluted sharesshares 128.59Mshares 130.83Mshares 129.17MUnavailableshares 128.42Mshares 127.95Mshares 127.38MUnavailableshares 126.95Mshares 126.40M
Pretax income-$8.02M$1.83M-$17.58M-$12.41M-$26.39M-$45.82M-$25.66M-$16.13M-$17.85M-$19.02M
Income tax expense-$475.00K-$412.00K-$472.00K-$2.52M$740.00K-$724.00K$266.00K-$804.00K-$150.00K-$375.00K
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$94.67M$90.89M$89.57M$86.95M$91.68M$95.82M$90.89M$85.98M$87.38M$85.00M
General & administrative$67.07M$63.61M$65.74M$63.51M$69.87M$71.75M$68.21M$63.64M$66.97M$63.33M
Selling & marketing$27.60M$27.28M$23.83M$23.44M$21.81M$24.08M$22.68M$22.34M$20.42M$21.68M

Balance

NEOGENOMICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Cash & equivalents$139.28M$145.54M$146.14M$159.62M$164.12M$154.72M$346.19M$367.01M$361.99M$355.08M
Total assets$1.38B$1.35B$1.35B$1.36B$1.37B$1.39B$1.60B$1.64B$1.64B$1.64B
Current assets$410.08M$381.48M$373.68M$376.29M$382.46M$392.55M$573.93M$596.02M$590.24M$584.20M
Total liabilities$576.28M$566.51M$517.77M$523.27M$536.49M$539.91M$713.16M$735.70M$732.90M$727.39M
Current liabilities$116.17M$105.88M$84.59M$88.30M$97.87M$100.12M$279.70M$301.24M$296.41M$289.96M
Total equity incl. NCI$800.64M$785.73M$828.76M$836.56M$838.29M$854.04M$888.27M$902.34M$908.21M$915.88M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$25.50M$27.14M$29.84M$28.57M$28.46M$34.17M$29.77M$26.75M$24.46M$23.21M
Accounts receivable$213.41M$175.40M$167.42M$159.24M$155.30M$153.12M$151.21M$150.54M$151.43M$146.58M
Goodwill$524.00M$524.00M$524.00M$524.34M$524.34M$524.14M$522.77M$522.77M$522.77M$522.77M
Long-term debt$374.69M$374.24MUnavailable$341.86MUnavailableUnavailableUnavailable$340.34MUnavailableUnavailable
Accounts payable$32.92M$20.95M$25.90M$23.09M$22.61M$27.49M$16.21M$21.61M$16.51M$17.19M

Cash flow

NEOGENOMICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Operating cash flow-$8.88M$19.96M-$8.14M$1.34M$8.88M$20.33M-$25.33M$9.80M$9.25M$13.89M
Capital expenditures$11.77M$8.22M$5.00M$7.87M$8.31M$6.32M$4.50M$11.60M$10.80M$13.08M
Investing cash flow-$11.85M-$8.32M-$5.00M-$6.30M-$277.00K-$9.31M$3.56M-$5.47M-$3.52M$7.31M
Financing cash flow$14.48M-$12.24M-$338.00K$431.00K$765.00K-$202.43M$949.00K$687.00K$1.18M$1.97M
Net change in cash-$6.26MUnavailableUnavailableUnavailable$9.39MUnavailableUnavailableUnavailable$6.91M$23.17M
Stock-based compensation$8.84M$8.22M$9.64M$8.04M$10.31M$12.21M$10.75M$8.33M$0$8.84M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$0UnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NEOGENOMICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Free cash flow-$20.66M$11.74M-$13.14M-$6.53M$570.00K$14.01M-$29.83M-$1.80M-$1.55M$814.00K
Gross margin46.2%45.6%43.3%43.8%42.8%42.6%43.6%44.9%44.6%44.1%
Operating margin-3.8%-4.8%-9.8%-7.1%-14.4%-26.3%-16.6%-10.7%-12.6%-13.3%
FCF margin-9.9%5.8%-7.0%-3.4%0.3%7.7%-17.8%-1.0%-0.9%0.5%
SBC / revenue4.2%4.1%5.2%4.2%5.5%6.7%6.4%4.8%Unavailable5.4%
Current ratio3.53x3.60x4.42x4.26x3.91x3.92x2.05x1.98x1.99x2.01x
Revenue YoY growth11.4%11.2%11.1%10.6%11.9%10.2%7.5%10.6%10.4%12.0%
Net margin-3.6%UnavailableUnavailable-5.2%-14.4%UnavailableUnavailable-8.9%-10.5%Unavailable
R&D / revenue4.7%5.3%5.1%4.8%4.6%5.0%6.1%4.6%4.6%4.8%
CapEx / revenue5.6%4.1%2.7%4.1%4.4%3.5%2.7%6.7%6.4%8.0%
Long-term debt / equity0.47xUnavailableUnavailable0.41xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable-22.6%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NEO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-28View SEC filing
10-Q · Filed 2026-07-28View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.